NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

@article{Stupp2012NovoTTF100AVP,
  title={NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.},
  author={Roger Stupp and Eric T. Wong and A A Kanner and David Steinberg and Herbert H. Engelhard and Volkmar Heidecke and Eilon D. Kirson and Sophie Taillibert and Frank Liebermann and Vladim{\'i}r Dbal{\'y} and Zvi Ram and John L Villano and Nikolai G. Rainov and Uri Weinberg and David Schiff and Lara J Kunschner and Jeffrey K Raizer and J{\'e}r{\^o}me Honnorat and Andrew Sloan and Mark G. Malkin and Joseph C. Landolfi and Franz Payer and Maximilian Mehdorn and Robert J. Weil and Susan C. Pannullo and Manfred Westphal and Martin Smr{\vc}ka and L. Chin and Herwig Kostron and Silvia Hofer and Jeffrey Bruce and Rees G. Cosgrove and Nina Paleologous and Yoram Palti and Philip H. Gutin},
  journal={European journal of cancer},
  year={2012},
  volume={48 14},
  pages={2192-202}
}
PURPOSE NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division. METHODS Phase III trial of chemotherapy-free treatment of NovoTTF (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent glioblastoma. Primary end-point was improvement of overall survival… CONTINUE READING